Sangrexx Approves 8-for-1 Reverse Stock Split Effective November 13
Key Facts
Sangrexx approved an 8-for-1 reverse split of its Class A and Class B common shares, effective November 13, 2026, according to a company filing with the U.S. Securities and Exchange Commission. The measure covers issued and unissued shares of both classes, the filing said. The company had said that every eight shares of the same class would be combined into one share of the corresponding class. An Investing.com report said trading in the shares adjusted for the split was expected to begin on November 16 on the Nasdaq Capital Market. The announced schedule thus separates the effective date from the start of adjusted trading.
The decision followed an extraordinary general meeting held by Sangrexx on November 3, 2026, at which shareholders approved all matters put to a vote, according to its filing with the SEC. This reflects shareholder approval of the split before its scheduled effective date of November 13. The decision covered issued and unissued shares, linking the current share count with the authorized capital structure. The information available in the filing did not state a specific reason for the split in November 2026. Accordingly, the measure is not attributed here to a stated purpose related to the share price or listing requirements.
For outstanding shares, the company expected Class A shares to fall from 4,035,192 to about 504,399 after the split, and Class B shares to decline from 96,043 to about 12,006, according to Investing.com, citing the company's announcement. The report said the final figures remain subject to rounding, explaining why post-split share counts were described as approximate. These changes show the effect of the 8-for-1 ratio on the number of shares in each class. Under the split mechanism, any fractional shares resulting from the transaction will be rounded up to the nearest whole common share, according to the company's SEC filing. This means the treatment of fractions could affect the final share count for the shareholders concerned, while the expected figures in the announcement remain approximate.
The adjustment also extends to authorized capital, with authorized shares falling from 200,000,000,000 to 25,000,000,000 when the decision takes effect, according to the company filing. At the same time, the par value per share will rise from $0.0003 to $0.0024, while stated capital remains at $60,000,000 under the amendment described in the filing. This change affects the legal structure of the shares alongside the expected reduction in outstanding shares. The filing linked the split's effective date to these new figures for capital and par value. This detail alone does not indicate a change in stated capital; it shows its par value being redistributed across a smaller number of authorized shares.
Sangrexx has carried out previous reverse stock splits, according to its annual report filed with the SEC. Those transactions included a 1-for-30 ratio in May 2023, a 1-for-60 ratio in January 2026, and a 1-for-5 ratio in August 2026. The annual report said the company carried out those splits to regain compliance with Nasdaq's minimum bid-price requirements and improve share tradability. This record places the new measure in a series of previous transactions, but does not independently specify the purpose of the November split. The disclosure of those earlier transactions also does not change the current split's scheduled effective date of November 13.
According to meeting data in the company filing, attendees represented about 0.88% of outstanding Class A shares, 100% of outstanding Class B shares, and about 35.71% of total voting power. The class representation percentages relate to the November 3 meeting date, while the voting-power percentage was based on the record date of October 22, 2026. On that date, the company had 3,545,018 outstanding Class A shares and 96,043 Class B shares, according to the filing. These figures provide context on the share base before the split and differ from the company's post-split estimates. The report published on Investing.com said the ticker symbol will remain SGRX and that the company will receive a new securities identification number, G21621142.